ReviewJournal of clinical and experimental hepatology2015
Portal vein thrombosis.
Review in Journal of clinical and experimental hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Visceral Thromboses in Pancreas Adenocarcinoma: Systematic Review.Clinical colorectal cancer · 2018Pooled it
- Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).Wiener klinische Wochenschrift · 2017Guideline
- Heparin combined with urokinase therapy for the treatment of acute portal vein thrombosis in children.Pediatric surgery international · 2026Article
- The PH score: a practical tool for screening myeloproliferative neoplasms in acute portal vein thrombosis.Thrombosis journal · 2026Article
- Imaging of spontaneous portosystemic shunts in portal hypertension: clinical significance and structured reporting.Abdominal radiology (New York) · 2026Review
- Incidence and clinicopathological analysis of portal vein and inferior vena cava thrombosis in autopsy cases of autosomal dominant polycystic kidney disease.Clinical and experimental nephrology · 2026Article
- The Effectiveness of Systemic Immune-Inflammation Index (SII) and Systemic Inflammation Response Index (SIRI) and Model for End-Stage Liver Disease (MELD) Score in Predicting Prognosis in Portal Vein Thrombosis, a Pilot Study.Diagnostics (Basel, Switzerland) · 2026Article
- Portal vein recanalization and transjugular intrahepatic portosystemic shunt in chronic portal vein thrombosis: a narrative review.Frontiers in radiology · 2026Review
- Ultrasound Characteristics of Budd-Chiari Syndrome: A Multicenter Analysis.Digestive diseases (Basel, Switzerland) · 2026Article
- Update in the treatment of cirrhotic patients with portal vein thrombosis.Clinical and molecular hepatology · 2025Review
- Pylephlebitis: A Rare but Redoubtable Complication of Intra-Abdominal Infections-A Series of 15 Cases.Life (Basel, Switzerland) · 2025Article
- Etiology and Risk Factors for Splanchnic Vein Thrombosis in Non-Cirrhotic, Non-Neoplastic Patients: A Narrative Review.Medicina (Kaunas, Lithuania) · 2025Review
- Endovascular Treatment for Acute Portal Vein Thrombosis.Interventional radiology (Higashimatsuyama-shi (Japan) · 2025Review
- Gut microbiota analysis in cirrhosis and non-cirrhotic portal hypertension suggests that portal hypertension can be main factor of cirrhosis-specific dysbiosis.Scientific reports · 2025Article
- Article
- Portal Hypertension Unmasked-Cavernous Transformation of the Portal Vein Following Portal Vein Thrombosis in a 9-Year-Old Female: A Case Report.Clinical case reports · 2025Article
- Application of intraluminal brachytherapy for malignant obstruction in the porta hepatis: a retrospective control study.Frontiers in oncology · 2025Review
- Article
- Prevalence and Risk Factors for Portal Cavernoma in Adult Patients with Portal Vein Thrombosis.Diagnostics (Basel, Switzerland) · 2024Article
- Portomesenteric Venous Thrombosis after Bariatric Surgery: A Case Series and Systematic Review Comparing LSG and LRYGB.Journal of personalized medicine · 2024Review
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Portal vein thrombosis is an important cause of portal hypertension. PVT occurs in association with cirrhosis or as a result of malignant invasion by hepatocellular carcinoma or even in the absence of associated liver disease. With the current research into its genesis, majority now have an underlying prothrombotic state detectable. Endothelial activation and stagnant portal blood flow also contribute to formation of the thrombus. Acute non-cirrhotic PVT, chronic PVT (EHPVO), and portal vein thrombosis in cirrhosis are the three main variants of portal vein thrombosis with varying etiological factors and variability in presentation and management. Procoagulant state should be actively investigated. Anticoagulation is the mainstay of therapy for acute non-cirrhotic PVT, with supporting evidence for its use in cirrhotic population as well. Chronic PVT (EHPVO) on the other hand requires the management of portal hypertension as such and with role for anticoagulation in the setting of underlying prothrombotic state, however data is awaited in those with no underlying prothrombotic states. TIPS and liver transplant may be feasible even in the setting of PVT however proper selection of candidates and type of surgery is warranted. Thrombolysis and thrombectomy have some role. TARE is a new modality for management of HCC with portal vein invasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.